title: HIV-associated lipodystrophy syndrome.
abstract: Highly active antiretroviral therapy (HAART) for human immunodeficiency virus-1 (HIV-1) and prophylactic therapy for opportunistic infections have increased survival. Adverse effects of HAART include lipid profile alterations, diabetes mellitus, and fat redistribution. These metabolic and physical changes are called the HIV-associated lipodystrophy syndrome. A link to protease inhibitors has been suggested, and more recently to nucleoside reverse transcriptase inhibitors and factors related to duration of HIV-1 infection itself.
authors.affiliation: Department of Pharmacy, University of North Carolina Hospitals and Clinics, Chapel Hill, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Qaqish
authors.forename: E
authors.initials: E
authors.lastname: Fisher
authors.forename: J
authors.initials: J
authors.lastname: Rublein
authors.forename: D A
authors.initials: DA
authors.lastname: Wohl
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D003920:Diabetes Mellitus / Q000139:chemically induced; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced*; D008074:Lipoproteins / Q000187:drug effects; D013577:Syndrome
chemical_list: D019380:Anti-HIV Agents; D008074:Lipoproteins